Skip to content

Cvs Health

NYSE: CVS · USD

Cvs Health cash flow and EPS82

Operating cash flow, capital investment, free cash flow and earnings per share.

Capital allocation

% of tracked cash uses

$3,342M
Cvs Health capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q280.65% · $625.3M5.07% · $39.3MUnavailable14.28% · $110.7MUnavailable100% · $775.3M
FY 2009 Q322.2% · $661.2M0.57% · $17M51.68% · $1,538.9M3.7% · $110.1M21.85% · $650.6M100% · $2,977.8M
FY 2009 Q441.86% · $795.5M3.04% · $57.7M49.37% · $938.1M5.69% · $108.2M0.04% · $0.7M100% · $1,900.2M
FY 2010 Q128.24% · $401M0.63% · $9M62.46% · $887M8.59% · $122M0.07% · $1M100% · $1,420M
FY 2010 Q215.69% · $465M0.54% · $16M20.69% · $613M4.02% · $119M59.06% · $1,750M100% · $2,963M
FY 2010 Q345.97% · $513M11.92% · $133M0% · $0M10.66% · $119M31.45% · $351M100% · $1,116M
FY 2010 Q481.83% · $626M2.48% · $19M0% · $0M15.56% · $119M0.13% · $1M100% · $765M
FY 2011 Q124.54% · $309M0.87% · $11M37.09% · $467M13.58% · $171M23.91% · $301M100% · $1,259M
FY 2011 Q216.5% · $401M55.74% · $1,355M20.73% · $504M6.99% · $170M0.04% · $1M100% · $2,431M
FY 2011 Q314.8% · $458M1.29% · $40M51.13% · $1,582M5.4% · $167M27.38% · $847M100% · $3,094M
FY 2011 Q430.27% · $704M1.5% · $35M19.26% · $448M7.14% · $166M41.83% · $973M100% · $2,326M
FY 2012 Q124.69% · $376M4.86% · $74M53.18% · $810M13.85% · $211M3.41% · $52M100% · $1,523M
FY 2012 Q221.66% · $442M9.8% · $200M58.21% · $1,188M10.24% · $209M0.1% · $2M100% · $2,041M
FY 2012 Q318.12% · $496M1.06% · $29M73.18% · $2,003M7.56% · $207M0.07% · $2M100% · $2,737M
FY 2012 Q423.99% · $716M2.51% · $75M11.03% · $329M6.77% · $202M55.7% · $1,662M100% · $2,984M
FY 2013 Q125.6% · $318M20.45% · $254M31.64% · $393M22.3% · $277M0% · $0M100% · $1,242M
FY 2013 Q241.79% · $486M3.96% · $46M30.52% · $355M23.73% · $276M0% · $0M100% · $1,163M
FY 2013 Q322.1% · $526M2.27% · $54M64.03% · $1,524M11.6% · $276M0% · $0M100% · $2,380M
FY 2013 Q424.34% · $654M2.27% · $61M63.42% · $1,704M9.97% · $268M0% · $0M100% · $2,687M
FY 2014 Q110.46% · $388M59.17% · $2,194M21.6% · $801M8.76% · $325MUnavailable100% · $3,708M
FY 2014 Q224.19% · $503M2.6% · $54M57.72% · $1,200M15.49% · $322MUnavailable100% · $2,079M
FY 2014 Q311.22% · $545M2.96% · $144M16.47% · $800M6.67% · $324M62.68% · $3,045M100% · $4,858M
FY 2014 Q430.73% · $700M2.06% · $47M52.68% · $1,200M13.92% · $317M0.61% · $14M100% · $2,278M
FY 2015 Q114.52% · $419M2.11% · $61M69.54% · $2,007M13.83% · $399MUnavailable100% · $2,886M
FY 2015 Q227.58% · $523M2.69% · $51M48.89% · $927M20.83% · $395MUnavailable100% · $1,896M
FY 2015 Q34.02% · $548M68.98% · $9,391M6.88% · $937M2.87% · $391M17.25% · $2,348M100% · $13,615M
FY 2015 Q420.05% · $877M45.08% · $1,972M25.83% · $1,130M8.94% · $391M0.09% · $4M100% · $4,374M
FY 2016 Q118.78% · $598M1.6% · $51M64.87% · $2,066M14.76% · $470MUnavailable100% · $3,185M
FY 2016 Q216.95% · $504M3.93% · $117M63.69% · $1,894M15.43% · $459MUnavailable100% · $2,974M
FY 2016 Q318.22% · $505M5.95% · $165M1.44% · $40M16.42% · $455M57.96% · $1,606M100% · $2,771M
FY 2016 Q424.7% · $617M8.25% · $206M18.45% · $461M18.25% · $456M30.34% · $758M100% · $2,498M
FY 2017 Q19.72% · $457M2.34% · $110M76.98% · $3,621M10.97% · $516MUnavailable100% · $4,704M
FY 2017 Q228.97% · $431M13.78% · $205M22.85% · $340M34.41% · $512MUnavailable100% · $1,488M
FY 2017 Q332.31% · $524M11.53% · $187M24.66% · $400M31.5% · $511MUnavailable100% · $1,622M
FY 2017 Q428.1% · $506M43.59% · $785M0% · $0M28.32% · $510MUnavailable100% · $1,801M
FY 2018 Q135.47% · $482M27.08% · $368MUnavailable37.38% · $508M0.07% · $1M100% · $1,359M
FY 2018 Q237.55% · $430M17.9% · $205MUnavailable44.54% · $510M0% · $0M100% · $1,145M
FY 2018 Q315.89% · $540M2.44% · $83MUnavailable15.01% · $510M66.66% · $2,265M100% · $3,398M
FY 2018 Q41.27% · $585M90.53% · $41,570MUnavailable1.11% · $510M7.09% · $3,256M100% · $45,921M
FY 2019 Q130.2% · $716M5.23% · $124MUnavailable27.37% · $649M37.2% · $882M100% · $2,371M
FY 2019 Q224.15% · $573M5.31% · $126MUnavailable27.69% · $657M42.86% · $1,017M100% · $2,373M
FY 2019 Q37.7% · $601M1.42% · $111MUnavailable8.27% · $646M82.61% · $6,451M100% · $7,809M
FY 2019 Q443.58% · $567M6.38% · $83MUnavailable50.04% · $651MUnavailable100% · $1,301M
FY 2020 Q124.61% · $742M20.33% · $613MUnavailable21.63% · $652M33.43% · $1,008M100% · $3,015M
FY 2020 Q235.16% · $448M12.17% · $155MUnavailable52.04% · $663M0.63% · $8M100% · $1,274M
FY 2020 Q34.97% · $534M0.56% · $60MUnavailable6.19% · $665M88.27% · $9,477M100% · $10,736M
FY 2020 Q410.91% · $713M0.58% · $38MUnavailable9.86% · $644M78.65% · $5,138M100% · $6,533M
FY 2021 Q117.95% · $829M1.82% · $84M0% · $0M14.21% · $656M66.02% · $3,049M100% · $4,618M
FY 2021 Q213.75% · $486M0.68% · $24M0% · $0M18.39% · $650M67.18% · $2,374M100% · $3,534M
FY 2021 Q316.46% · $608M0.73% · $27M0% · $0M17.84% · $659M64.97% · $2,400M100% · $3,694M
FY 2021 Q416.14% · $597M0.3% · $11M0% · $0M17.84% · $660M65.72% · $2,431M100% · $3,699M
FY 2022 Q127.7% · $1,051M0.18% · $7M52.71% · $2,000M19.03% · $722M0.37% · $14M100% · $3,794M
FY 2022 Q214.67% · $408M4.24% · $118M0% · $0M26.61% · $740M54.48% · $1,515M100% · $2,781M
FY 2022 Q314.58% · $580M0.15% · $6M0% · $0M18.25% · $726M67.02% · $2,666M100% · $3,978M
FY 2022 Q423.47% · $688M0.27% · $8M51.18% · $1,500M24.53% · $719M0.55% · $16M100% · $2,931M
FY 2023 Q18.76% · $984M63.13% · $7,094M17.96% · $2,018M6.93% · $779M3.22% · $362M100% · $11,237M
FY 2023 Q24.85% · $591M76.94% · $9,380MUnavailable6.52% · $795M11.69% · $1,425M100% · $12,191M
FY 2023 Q323.81% · $545M0.79% · $18MUnavailable34.03% · $779M41.37% · $947M100% · $2,289M
FY 2023 Q440.63% · $911M5.35% · $120MUnavailable34.75% · $779M19.27% · $432M100% · $2,242M
FY 2024 Q115.28% · $705M0.54% · $25M65.59% · $3,027M18.2% · $840M0.39% · $18M100% · $4,615M
FY 2024 Q240.82% · $638M3.07% · $48MUnavailable54.89% · $858M1.22% · $19M100% · $1,563M
FY 2024 Q321.02% · $670M0.38% · $12MUnavailable26.25% · $837M52.35% · $1,669M100% · $3,188M
FY 2024 Q416.4% · $768M0.21% · $10M0% · $0M17.89% · $838M65.49% · $3,067M100% · $4,683M
FY 2025 Q131.67% · $743M0.85% · $20M0% · $0M35.81% · $840M31.67% · $743M100% · $2,346M
FY 2025 Q237.68% · $607M7.39% · $119M0% · $0M53.76% · $866M1.18% · $19M100% · $1,611M
FY 2025 Q314.91% · $698M6.2% · $290M0% · $0M18.07% · $846M60.82% · $2,847M100% · $4,681M
FY 2025 Q447.34% · $784M0.42% · $7M0% · $0M51.03% · $845M1.21% · $20M100% · $1,656M
FY 2026 Q126.37% · $849M0.16% · $5MUnavailable26.31% · $847M47.16% · $1,518M100% · $3,219M
FY 2026 Q220.68% · $691M0.12% · $4MUnavailable26.27% · $878M52.93% · $1,769M100% · $3,342M
Jun 30, 2009 through Jun 30, 2026

Latest period omits buybacks. Percentages cover tracked uses. SBC is noncash and excluded.

Operating cash flow

USD millions

$6,345M

Capital expenditures

USD millions

$691M

Free cash flow

USD millions

$5,654M

Stock-based compensation

USD millions

$176M

SBC / free cash flow

% · FCF before SBC deduction

3.11%

SBC / operating cash flow

%

2.77%

Software & intangible investment

USD millions

—

Separately disclosed software and intangible investment is unavailable in the extracted statements for this period.

Diluted EPS

USD per share

$2.31

Quarterly data

Cvs Health cash-flow history. Each metric has its own unit. A dash means inputs are missing or the calculation is undefined.
Fiscal periodEndedOperating cash flowUSD millionsCapital expendituresUSD millionsFree cash flowUSD millionsStock-based compensationUSD millionsSBC / free cash flow%SBC / operating cash flow%Software & intangible investmentUSD millionsDiluted EPSUSD per share
FY 2026 Q2Jun 30, 20266,3456915,6541763.11%2.77%—$2.31
FY 2026 Q1Mar 31, 20264,2498493,4002667.82%6.26%—$2.3
FY 2025 Q4Dec 31, 20253,3907842,6061355.18%3.98%——
FY 2025 Q3Sep 30, 202579669898138140.82%17.34%—$-3.13
FY 2025 Q2Jun 30, 20251,8976071,29013610.54%7.17%—$0.8
FY 2025 Q1Mar 31, 20254,5567433,8131263.3%2.77%—$1.41
FY 2024 Q4Dec 31, 20241,8607681,09213712.55%7.37%——
FY 2024 Q3Sep 30, 2024-745670-1,415133———$0.07
FY 2024 Q2Jun 30, 20243,0896382,4511335.43%4.31%—$1.41
FY 2024 Q1Mar 31, 20244,9037054,1981373.26%2.79%—$0.88
FY 2023 Q4Dec 31, 2023-2,636911-3,547127————
FY 2023 Q3Sep 30, 20232,7165452,1711547.09%5.67%—$1.75
FY 2023 Q2Jun 30, 20235,9085915,3172043.84%3.45%—$1.48
FY 2023 Q1Mar 31, 20237,4389846,4541031.6%1.38%—$1.65
FY 2022 Q4Dec 31, 2022-1,952688-2,640106————
FY 2022 Q3Sep 30, 20229,1235808,5431051.23%1.15%—$-2.6
FY 2022 Q2Jun 30, 20225,4434085,0351472.92%2.7%—$2.23
FY 2022 Q1Mar 31, 20223,5631,0512,512893.54%2.5%—$1.74
FY 2021 Q4Dec 31, 20214,0055973,4081384.05%3.45%——
FY 2021 Q3Sep 30, 20215,5216084,9131142.32%2.06%—$1.2
FY 2021 Q2Jun 30, 20215,8474865,3611452.7%2.48%—$2.1
FY 2021 Q1Mar 31, 20212,8928292,063874.22%3.01%—$1.68
FY 2020 Q4Dec 31, 20203,5677132,8541123.92%3.14%——
FY 2020 Q3Sep 30, 20201,8745341,3401098.13%5.82%—$0.93
FY 2020 Q2Jun 30, 20207,1194486,671831.24%1.17%—$2.26
FY 2020 Q1Mar 31, 20203,3057422,563963.75%2.9%—$1.53
FY 2019 Q4Dec 31, 20192,6345672,067984.74%3.72%—$1.33
FY 2019 Q3Sep 30, 20192,9286012,3271295.54%4.41%—$1.17
FY 2019 Q2Jun 30, 20195,3385734,7651122.35%2.1%—$1.49
FY 2019 Q1Mar 31, 20191,9487161,2321149.25%5.85%—$1.09
FY 2018 Q4Dec 31, 20182,4795851,8941085.7%4.36%—$-0.37
FY 2018 Q3Sep 30, 20181,0975405576211.13%5.65%—$1.36
FY 2018 Q2Jun 30, 20182,9344302,504552.2%1.87%—$-2.52
FY 2018 Q1Mar 31, 20182,3554821,873552.94%2.34%—$0.98
FY 2017 Q4Dec 31, 2017-136506-64261———$3.22
FY 2017 Q3Sep 30, 20172,6115242,087653.11%2.49%—$1.26
FY 2017 Q2Jun 30, 20171,9994311,568533.38%2.65%—$1.07
FY 2017 Q1Mar 31, 20173,5334573,076551.79%1.56%—$0.92
FY 2016 Q4Dec 31, 20162,1216171,504563.72%2.64%—$1.59
FY 2016 Q3Sep 30, 20163,9255053,420591.73%1.5%—$1.43
FY 2016 Q2Jun 30, 20161,6115041,107504.52%3.1%—$0.86
FY 2016 Q1Mar 31, 20162,4125981,814573.14%2.36%—$1.04
FY 2015 Q4Dec 31, 20153,5718772,694552.04%1.54%—$1.34
FY 2015 Q3Sep 30, 20151,8205481,272876.84%4.78%—$1.11
FY 2015 Q2Jun 30, 20151,037523514448.56%4.24%—$1.12
FY 2015 Q1Mar 31, 20151,9844191,565442.81%2.22%—$1.07
FY 2014 Q4Dec 31, 20143,4237002,723441.62%1.29%—$1.14
FY 2014 Q3Sep 30, 20141,6455451,100444%2.67%—$0.81
FY 2014 Q2Jun 30, 20148975033944210.66%4.68%—$1.06
FY 2014 Q1Mar 31, 20142,1723881,784351.96%1.61%—$0.95
FY 2013 Q4Dec 31, 20131,538654884404.52%2.6%—$1.05
FY 2013 Q3Sep 30, 20131,7035261,177352.97%2.06%—$1.02
FY 2013 Q2Jun 30, 2013902486416327.69%3.55%—$0.91
FY 2013 Q1Mar 31, 20131,6403181,322342.57%2.07%—$0.77
FY 2012 Q4Dec 31, 20121,7317161,015353.45%2.02%—$0.9
FY 2012 Q3Sep 30, 2012923496427337.73%3.58%—$0.79
FY 2012 Q2Jun 30, 20121,231442789283.55%2.27%—$0.75
FY 2012 Q1Mar 31, 20122,7863762,410361.49%1.29%—$0.59
FY 2011 Q4Dec 31, 20118217041173529.91%4.26%—$0.81
FY 2011 Q3Sep 30, 20111,9624581,504352.33%1.78%—$0.65
FY 2011 Q2Jun 30, 20111,207401806293.6%2.4%—$0.6
FY 2011 Q1Mar 31, 20111,8663091,557362.31%1.93%—$0.52
FY 2010 Q4Dec 31, 20101,7756261,149383.31%2.14%—$0.75
FY 2010 Q3Sep 30, 20101,292513779374.75%2.86%—$0.59
FY 2010 Q2Jun 30, 20106524651873820.32%5.83%—$0.6
FY 2010 Q1Mar 31, 20101,060401659375.61%3.49%—$0.55
FY 2009 Q4Dec 31, 20091,804.4795.51,008.952.45.19%2.9%—$0.74
FY 2009 Q3Sep 30, 2009907.4661.2246.237.815.35%4.17%—$0.71
FY 2009 Q2Jun 30, 2009552.2625.3-73.152.8—9.56%—$0.6
Sources and calculations

Financial inputs from company filings. Last checked Oct 18, 2026. A dash means missing inputs or an undefined calculation.

Period changes use the preceding fiscal quarter or year. Percentage changes divide by the absolute prior value; a zero or missing baseline has no percentage change. Percentage metrics show changes in percentage points.

FCF subtracts reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Acquisitions and noncash lease additions are excluded. EPS and weighted shares are not summed across quarters. Annual figures use annual reports.

SBC / FCF always uses FCF before SBC deduction; both SBC ratios compare amounts from the same period. A zero or negative cash-flow denominator is undefined, and values above 100% are retained.

Each reported nonnegative cash use / sum of available tracked nonnegative cash uses × 100. Missing categories are omitted, never set to zero. This is the composition of tracked uses, not a complete cash-flow reconciliation or a percentage of OCF. SBC is noncash and excluded. Negative amounts are excluded as reversals or net receipts; they are not converted to spending. Annual bars use reported annual amounts. Turning off a category hides its share without changing the denominator. Debt repayments prefer a reported aggregate, with long-term or convertible-only scope identified in the tooltip. Acquisitions are net of cash acquired. Dividend payments use the aggregate where reported, including dividend equivalents when part of that concept.

The SBC option subtracts reported share-based compensation from FCF as an economic-cost scenario. Missing SBC never becomes zero.

Market prices: Yahoo Finance · CVS, USD. Latest completed close Sep 25, 2026. Price data retrieved Sep 28, 2026.

Operating cash flow
Reported net cash provided by or used in operating activities.
Capital expenditures
Reported cash capital investment. Uses purchases of property, plant and equipment where disclosed; otherwise purchases of productive assets, which can also include software and intangibles. Excludes acquisitions and noncash lease additions.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Stock-based compensation
Reported share-based compensation addback in the cash-flow statement. Missing disclosure is not treated as zero.
SBC / free cash flow
Reported share-based compensation / (operating cash flow − cash capital investment) × 100, for the same fiscal period. Always uses FCF before SBC deduction. Zero or negative FCF is undefined; values above 100% are retained.
SBC / operating cash flow
Reported share-based compensation / reported operating cash flow × 100, for the same fiscal period. Zero or negative operating cash flow is undefined. Unaffected by the SBC deduction scenario.
Software & intangible investment
Separately tagged payments for capitalized software under US GAAP, or purchases of intangible assets under IFRS. This optional disclosure is not inferred from total capex or deducted a second time from FCF.
Diluted EPS
Reported diluted earnings per share, normalized for recorded subsequent stock splits. Quarterly EPS is never subtracted from annual or YTD EPS.